GEN Exclusives

More »

GEN News Highlights

More »
Mar 22, 2011

Novartis Completes $125M Acquisition of Majority Stake in Chinese Vaccines Firm

  • Novartis has completed its acquisition of 85% of Chinese vaccines firm Zhejiang Tianyuan Bio-Pharmaceutical. The roughly $125 million deal was first announced in November 2009. Swiss drugs giant Novartis says the acquisition will provide it with an expanded presence in the Chinese vaccines market and facilitate the introduction of additional Novartis vaccines into the country. The firms claim China represents the world’s third largest vaccines market, with annual industry sales of over $1 billion, and the expectation of double-digit growth over coming years. “This agreement combines the strength of our vaccines R&D strategy and pipeline with Tianyuan’s deep knowledge of the vaccines market in China,” remarks Andrin Oswald, head of Novartis vaccines and diagnostics.

    Novartis and Tianyuan will work together to expand the Chinese firm’s product portfolio and R&D pipeline through targeted investments in technology, manufacturing, and commercial networks. “We have already identified several joint development programs that could be implemented in China over the next ten years, with the potential of launching key products responding to unmet medical needs in the mid-term," claims Ding Xiaohang, founder, chairman, and CEO of Tianyuan.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Should the CDC Director Resign?

Do you think the CDC chief should resign?